利奈唑胺治疗院内MRSA肺炎的临床评价  

Clinical evaluation of linezolid for MRSA-related HAP

作　　者：毕鸿雁[1] 杨宏军[1] 田风[1] 

机构地区：[1]昆明医学院第一附属医院干疗科,650031

出　　处：《中国老年保健医学》2009年第6期38-39,共2页Chinese Journal of Geriatric Care

摘　　要：目的评价利奈唑胺治疗院内MRSA肺炎的临床疗效和安全性。方法回顾分析13例MRSA感染的住院患者接受利奈唑胺治疗临床资料。结果临床治愈13例,不良反应发生率7.7%。结论应用利奈唑胺治疗院内MRSA肺炎能取得显著的临床效果及满意的细菌清除率,可作为院内MRSA肺炎的有效用药。Objective To evaluate therapeutic effect and drug safety of Linezolid in MRSA-related Hospital-associated Pneumonia（HAP） therapy. Methods Retrospective analysis the clinical of 13 patients,suffered form MRSA-related HAP,who treated with Linezolid. Results All patients get cured at clinical therapy criterion,and medicine adverse-reaction rate is 7.7%. Conclusion Linezolid could provide conspicuous effectiveness and satisfactory bacterium clearance rate in treatment of MRSA-related HAP,which would become the effective medicine for this disease.

关 键 词：利奈唑胺 MRSA肺炎 院内 

分 类 号：R563.1[医药卫生—呼吸系统] R978.1[医药卫生—内科学]